Intensity Therapeutics Raises $6.6 Million to Advance Cancer Treatment Research

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, has announced the successful raising of $6.6 million in gross proceeds through at-the-market (ATM) stock sales in July 2025. This financial boost is set to support the company's ongoing clinical trials, particularly for its lead investigational product, INT230-6, which is designed for direct intratumoral injection to combat cancer. The ATM sales involved 19,868,658 shares at an average price of $0.3323 per share, leaving the company with 46,035,081 shares of common stock issued and outstanding as of July 31, 2025.

Lewis H. Bender, President and CEO of Intensity Therapeutics, highlighted the strategic advantage of the ATM sales, noting the favorable pricing and lower costs compared to previous offerings. This approach not only strengthens the company's balance sheet but also ensures the continuation of clinical trials into the latter half of 2026. The success of these sales underscores the market's confidence in Intensity Therapeutics' innovative approach to cancer treatment, which aims to kill tumors and enhance the immune system's ability to recognize cancers.

INT230-6, developed using Intensity's proprietary DfuseRx℠ technology platform, combines two potent anti-cancer agents with a diffusion enhancer to facilitate the dispersion of cytotoxic drugs throughout tumors. This method promises local disease control and direct tumor killing, alongside stimulating an immune response without the immunosuppressive effects typical of systemic chemotherapy. The company's clinical trials, including Phase 3 studies in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, are pivotal in evaluating the efficacy of INT230-6. For more information on Intensity Therapeutics and its groundbreaking research, visit https://www.intensitytherapeutics.com.